FY2029 EPS Estimates for Nuvalent Decreased by HC Wainwright

Nuvalent, Inc. (NASDAQ:NUVL) – Analysts at HC Wainwright cut their FY2029 earnings per share estimates for shares of Nuvalent in a note issued to investors on Monday, March 2nd. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings per share of $6.52 for the year, down from their prior estimate of $6.77. HC Wainwright currently has a “Buy” rating and a $155.00 price objective on the stock. The consensus estimate for Nuvalent’s current full-year earnings is ($3.86) per share.

Several other research firms have also commented on NUVL. JPMorgan Chase & Co. lowered their price objective on Nuvalent from $147.00 to $145.00 and set an “overweight” rating on the stock in a research report on Friday, December 19th. The Goldman Sachs Group increased their price target on shares of Nuvalent from $120.00 to $135.00 and gave the stock a “buy” rating in a report on Tuesday, November 18th. Canaccord Genuity Group initiated coverage on shares of Nuvalent in a research report on Wednesday, November 12th. They set a “buy” rating and a $126.00 price target on the stock. Barclays set a $152.00 price objective on shares of Nuvalent in a research report on Monday, November 17th. Finally, Truist Financial set a $140.00 target price on Nuvalent in a research report on Monday, November 24th. Fifteen research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $138.67.

Nuvalent Stock Down 2.5%

Nuvalent stock opened at $100.13 on Wednesday. The business’s 50-day moving average price is $103.14 and its 200 day moving average price is $95.72. The firm has a market cap of $7.28 billion, a price-to-earnings ratio of -17.12 and a beta of 1.32. Nuvalent has a 52 week low of $55.53 and a 52 week high of $113.01.

Insider Buying and Selling

In other news, insider Deborah Ann Miller sold 14,300 shares of Nuvalent stock in a transaction that occurred on Thursday, January 22nd. The stock was sold at an average price of $110.16, for a total value of $1,575,288.00. Following the sale, the insider directly owned 59,634 shares of the company’s stock, valued at $6,569,281.44. The trade was a 19.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Henry E. Pelish sold 2,664 shares of the business’s stock in a transaction that occurred on Tuesday, January 6th. The stock was sold at an average price of $97.17, for a total value of $258,860.88. Following the sale, the insider owned 65,888 shares of the company’s stock, valued at $6,402,336.96. The trade was a 3.89% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 76,463 shares of company stock worth $7,722,489 in the last quarter. 10.20% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. AQR Capital Management LLC grew its holdings in shares of Nuvalent by 64.8% during the first quarter. AQR Capital Management LLC now owns 9,874 shares of the company’s stock worth $700,000 after buying an additional 3,881 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in Nuvalent by 54.4% during the first quarter. Goldman Sachs Group Inc. now owns 453,620 shares of the company’s stock worth $32,171,000 after acquiring an additional 159,873 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in Nuvalent by 8.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 149,941 shares of the company’s stock valued at $10,634,000 after acquiring an additional 12,123 shares in the last quarter. Intech Investment Management LLC raised its holdings in Nuvalent by 28.7% in the 1st quarter. Intech Investment Management LLC now owns 19,262 shares of the company’s stock valued at $1,366,000 after acquiring an additional 4,293 shares during the last quarter. Finally, Teacher Retirement System of Texas lifted its stake in Nuvalent by 9.9% in the 2nd quarter. Teacher Retirement System of Texas now owns 10,675 shares of the company’s stock worth $815,000 after purchasing an additional 964 shares in the last quarter. Hedge funds and other institutional investors own 97.26% of the company’s stock.

Nuvalent News Roundup

Here are the key news stories impacting Nuvalent this week:

• Positive Sentiment: HC Wainwright raised quarterly EPS forecasts for Q1–Q4 2026 and mid‑2026 quarters (cuts to expected losses: Q1 to ($1.26), Q2 to ($1.21), Q3 to ($1.16), Q4 to ($0.94)), and improved FY2026 to ($4.57) from a larger loss — signaling an expectation for accelerating progress toward profitability. MarketBeat article
• Positive Sentiment: HC Wainwright increased long‑range profitability views for FY2028 and FY2030 (FY2028 to $2.11 EPS from $1.75; FY2030 at $2.59), indicating confidence in Nuvalent’s longer-term product/market potential. MarketBeat article
• Neutral Sentiment: HC Wainwright maintained a Buy rating and a $155 price target — a bullish signal that may support upside if operational/clinical catalysts meet expectations, but it’s based on multi‑year recovery assumptions. MarketBeat article
• Neutral Sentiment: Market context: the company still shows a consensus near‑term full‑year loss (current consensus FY2026 ≈ ($3.86) per share) and a relatively high beta, so revisions can produce outsized intraday moves. MarketBeat article
• Negative Sentiment: HC Wainwright lowered FY2027 and FY2029 forecasts (FY2027 to ($2.06) from ($1.69); FY2029 to $6.52 from $6.77), showing some downward revision to intermediate/out‑year expectations and adding uncertainty to the profit ramp timeline. MarketBeat article

About Nuvalent

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.